Spots Global Cancer Trial Database for keytruda
Every month we try and update this database with for keytruda cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | NCT03435952 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Pembrolizumab Clostridium Nov... Doxycycline | 18 Years - | M.D. Anderson Cancer Center | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON) | NCT04569461 | Prostate Cancer | pembrolizumab Stereotactic bo... Short-term andr... Radical Prostat... | 18 Years - | Duke University | |
| Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) | NCT03391973 | Carcinoma of Un... | Pembrolizumab I... | 18 Years - | AHS Cancer Control Alberta | |
| Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy | NCT04130542 | Cancer | LVGN6051 KEYTRUDA® (pemb... | 18 Years - | Lyvgen Biopharma Holdings Limited | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) | NCT03391973 | Carcinoma of Un... | Pembrolizumab I... | 18 Years - | AHS Cancer Control Alberta | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | NCT05047094 | Head and Neck S... Skin Cancer Metastatic Head... | Diffusing Alpha... Pembrolizumab | 18 Years - | Alpha Tau Medical LTD. | |
| Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | NCT02879760 | Non-Small Cell ... | Ad-MAGEA3 MG1-MAGEA3 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. | |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC | NCT03184571 | Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ... | Bemcentinib; pe... | 18 Years - | BerGenBio ASA | |
| Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | NCT02719015 | Melanoma | rAd.CD40L Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NCT05877430 | NSCLC HNSCC Melanoma Metastatic Canc... Advanced Solid ... Advanced Cancer | CJRB-101 Pembrolizumab i... | 18 Years - | CJ Bioscience, Inc. | |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | NCT06295731 | Head and Neck S... | INBRX-106 Pembrolizumab | 18 Years - | Inhibrx, Inc. | |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | NCT02575404 | Melanoma Non-Small Cell ... Squamous Cell C... | GR-MD-02 Pembrolizumab | 18 Years - | Providence Health & Services | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | NCT04834973 | Melanoma | tigilanol tigla... pembrolizumab | 18 Years - | QBiotics Group Limited | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | NCT04924062 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. | |
| Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors | NCT03043664 | Gastroenteropan... | Lanreotide Pembrolizumab | 18 Years - | Duke University | |
| Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | NCT05739006 | Melanoma Non Small Cell ... | BCD-201 Keytruda | 18 Years - | Biocad | |
| Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | NCT04453046 | Squamous Cell C... | Hemopurifier Pembrolizumab 2... | 18 Years - | Aethlon Medical Inc. | |
| Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | NCT03131908 | Melanoma and Ot... Metastatic Mela... | GSK2636771 Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Renal Retention in High Grade Upper Tract Urothelial Cancer | NCT05656235 | High Grade Urot... Bladder Cancer Urothelial Carc... | Enfortumab vedo... Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | NCT04306900 | Solid Tumor, Ad... | TTX-030, budiga... TTX-030, budiga... TTX-030 and mFO... TTX-030 and bud... TTX-030, budiga... TTX-030 and pem... TTX-030, nab-pa... Budigalimab and... | 18 Years - 110 Years | Trishula Therapeutics, Inc. | |
| Renal Retention in High Grade Upper Tract Urothelial Cancer | NCT05656235 | High Grade Urot... Bladder Cancer Urothelial Carc... | Enfortumab vedo... Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab | NCT03263039 | Transitional Ce... Biomarkers | Pembrolizumab | 18 Years - | Erasmus Medical Center | |
| Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab | NCT03263039 | Transitional Ce... Biomarkers | Pembrolizumab | 18 Years - | Erasmus Medical Center | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma | NCT05986331 | Melanoma (Skin) | BCD-201 Keytruda | 18 Years - | Biocad | |
| Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | NCT05062980 | Non Small Cell ... | quaratusugene o... pembrolizumab docetaxel ramucirumab Investigator's ... | 18 Years - | Genprex, Inc. | |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC | NCT03184571 | Lung Cancer Met... NSCLC Stage IV Adenocarcinoma ... | Bemcentinib; pe... | 18 Years - | BerGenBio ASA | |
| Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | NCT04627012 | Hepatocellular ... Anti-PD1 Antibo... Liver Diseases | Lenvatinib Opdivo Camrelizumab Keytruda Toripalimab Sintilimab Tislelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) | NCT04592653 | Advanced Solid ... | Nemvaleukin alf... Pembrolizumab | 18 Years - | Mural Oncology, Inc | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | NCT06348199 | Non-small Cell ... | SB27 Keytruda | 18 Years - | Samsung Bioepis Co., Ltd. | |
| Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | NCT04847466 | Gastroesophagea... Advanced HNSCC | N-803 Pembrolizumab PD-L1 t-haNK | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) | NCT04003636 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | NCT05323656 | Squamous Cell C... | Setanaxib Pembrolizumab Placebo | 18 Years - | Calliditas Therapeutics AB | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | NCT02289209 | Recurrent Head ... Carcinoma, Squa... | Reirradiation MK-3475 | 18 Years - | University of Pittsburgh | |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | NCT05849480 | Biliary Cancer Bile Duct Cance... Cancer of the B... | oxaliplatin capecitabine Keytruda CDX-1140 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | NCT04258683 | Multiple Myelom... | Pembrolizumab | 18 Years - | Canadian Myeloma Research Group | |
| Clinical Trial of TB511 in Advanced Solid Tumors | NCT06400160 | NSCLC Prostate Cancer Colorectal Canc... Hepatocellular ... | TB511 Keytruda | 19 Years - | Twinpig Biolab, Inc. | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | NCT03861793 | Advanced Solid ... | ALKS 4230 Pembrolizumab | 18 Years - | Mural Oncology, Inc | |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | NCT05849480 | Biliary Cancer Bile Duct Cance... Cancer of the B... | oxaliplatin capecitabine Keytruda CDX-1140 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | NCT03562871 | NSCLC | IO102 pembrolizumab (... Carboplatin (Ca... Pemetrexed (Pem... | 18 Years - | IO Biotech | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| OH2 Injection in Solid Tumors | NCT04386967 | Solid Tumor Melanoma | OH2 injection Keytruda | 18 Years - 75 Years | Binhui Biopharmaceutical Co., Ltd. | |
| Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | NCT06430866 | Early-stage Non... | ABP 234 Pembrolizumab | 18 Years - | Amgen | |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | NCT02575404 | Melanoma Non-Small Cell ... Squamous Cell C... | GR-MD-02 Pembrolizumab | 18 Years - | Providence Health & Services | |
| APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | NCT02706353 | Melanoma | APX005M Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy | NCT04130542 | Cancer | LVGN6051 KEYTRUDA® (pemb... | 18 Years - | Lyvgen Biopharma Holdings Limited | |
| Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | NCT05062980 | Non Small Cell ... | quaratusugene o... pembrolizumab docetaxel ramucirumab Investigator's ... | 18 Years - | Genprex, Inc. | |
| A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer | NCT04144517 | Non-cutaneous S... | ALKS 4230 Pembrolizumab | 18 Years - | Mural Oncology, Inc | |
| Pembro/Carbo/Taxol in Endometrial Cancer | NCT02549209 | Endometrial Can... Endometrial Ade... | Pembrolizumab Paclitaxel Carboplatin | 18 Years - | Big Ten Cancer Research Consortium | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | NCT04116320 | Melanoma Breast Cancer Merkel Cell Car... Squamous Cell C... Non Small Cell ... Cervical Cancer Urothelial Carc... Ovarian Cancer Hepatocellular ... Small-cell Lung... Microsatellite ... Gastric Cancer Esophageal Canc... | Echopulse Poly ICLC Standard of Car... | 18 Years - | University of Virginia | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) | NCT04003636 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | NCT05739006 | Melanoma Non Small Cell ... | BCD-201 Keytruda | 18 Years - | Biocad | |
| A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | NCT06348199 | Non-small Cell ... | SB27 Keytruda | 18 Years - | Samsung Bioepis Co., Ltd. | |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | NCT03184558 | Triple Negative... Inflammatory Br... | Bemcentinib; pe... | 18 Years - | BerGenBio ASA | |
| Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab | NCT02515227 | Melanoma | 6MHP Pembrolizumab | 18 Years - | University of Virginia | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. | |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NCT05877430 | NSCLC HNSCC Melanoma Metastatic Canc... Advanced Solid ... Advanced Cancer | CJRB-101 Pembrolizumab i... | 18 Years - | CJ Bioscience, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
